Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 60-70

  Werle, Martin ^a  

^a Thiomatrix Forschungs und Beratungs GmbH   (Austria)

Author keywords

Efflux pump inhibitors; Oral drug delivery; P glycoprotein; P gp inhibitors; Polymeric inhibitors

Indexed keywords

AMIKACIN; AMIODARONE; ATORVASTATIN; BIRICODAR; CHLORPROMAZINE; CREMOPHOR; CYCLOSPORIN; DIGOXIN; DOCETAXEL; ETOPOSIDE; FELODIPINE; GEMFIBROZIL; ISOTHIOCYANIC ACID DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; KR 30031; LEUKOTRIENE C4; MACROGOL STEARATE; NIFEDIPINE; PACLITAXEL; POLYMER; PROBENECID; QUINIDINE; RITONAVIR; SULINDAC; TACROLIMUS; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL DERIVATIVE;

COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG TRANSPORT; ENZYME ACTIVITY; IN VIVO STUDY; INTESTINE ABSORPTION; MOLECULAR WEIGHT; NONHUMAN; REVIEW;

EID: 38349162946     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21090     Document Type: Article

References (67)

1. Woodley JF. 1994. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11:61-95.
2. Bernkop-Schnürch A. 1998. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 52:1-16.
3. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
5. Friend DR. 2004. Drug delivery to the small intestine. Curr Gastroenteral Rep 6:371-376.
6. Crivori P, Reinach B, Pezzetta D, Poggesi I. 2006. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 3:33-44.
7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. 2002. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
8. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW. 2006. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27:195-203.
9. Werle M, Hoffer M. 2006. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release 111:41-46.
10. Hugger ED, Audus KL, Borchardt RT. 2002. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 91:1980-1990.
11. Tang F, Ouyang H, Yang JZ, Borchardt RT. 2004. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. J Pharm Sci 93:1185-1194.
12. Florea BI, van der Sandt IC, Schrier SM, Kooiman K, Deryckere K, de Boer AG, Junginger HE, Borchard G. 2001. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br J Pharmacol 134:1555-1563.
13. al-Shawi MK, Urbatsch IL, Senior AE. 1994. Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 269:8986-8992.
14. Romiti N, Tramonti G, Donati A, Chieli E. 2004. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 76:293-302.
15. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2004. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856-864.
16. Bailey DG, Dresser GK. 2004. Natural products and adverse drug interactions. CMAJ 170:1531-1532.
17. Jodoin J, Demeule M, Beliveau R. 2002. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149-159.
18. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. 2003. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 48:347-359.
19. Twentyman PR, Bleehen NM. 1991. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27:1639-1642.
20. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW. 1997. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140.
21. Leu BL, Huang JD. 1995. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432-436.
22. Malingre MM, Ten Bokkel Huinink WW, Mackay M, Schellens JH, Beijnen JH. 2001. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol 57:305-307.
23. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. 2001. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
24. Lennernas H. 2003. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
25. Woo JS, Lee CH, Shim CK, Hwang SJ. 2003. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30.
26. Choi JS, Choi HK, Shin SC. 2004. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165-170.
27. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. 2002. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49:322-328.
28. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. 2004. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 22:219-229.
29. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O. 2000. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421.
30. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183.
31. Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH. 2005. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 55:72-78.
32. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73:51-60.
33. Khan SI, Abourashed EA, Khan IA, Walker LA. 2003. Transport of parthenolide across human intestinal cells (Caco-2). Planta Med 69:1009-1012.
34. Walgren RA, Karnaky KJJ, Lindenmayer GE, Walle T. 2000. Efflux of dietary flavonoid quercetin 4′-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294:830-836.
35. Lowes S, Cavet ME, Simmons NL. 2003. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49-56.
36. Potschka H, Baltes S, Loscher W. 2004. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 58:85-91.
37. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. 2002. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16:1743-1747.
38. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160-1167.
39. Seral C, Carryn S, Tulkens PM, Van Bambeke F. 2003. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51:1167-1173.
40. Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W, Milton J, Wren SP, Vicker N, Depledge P, Scott J, Smith L, Jones H, Mistry P, Faint R, Thompson D, Cocks S. 2004. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J Med Chem 47:1329-1338.
41. O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M. 2004. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457-464.
42. Hu K, Morris ME. 2004. Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci 93:1901-1911.
43. Hugger ED, Cole CJ, Raub TJ, Burton PS, Borchardt RT. 2003. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J Pharm Sci 92:21-26.
44. Batrakova EV, Li S, Miller DW, Kabanov AV. 1999. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 16:1366-1372.
45. Bromberg L, Alakhov V. 2003. Effects of polyethermodified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 88:11-22.
46. Banerjee SK, Jagannath C, Hunter RL, Dasgupta A. 2000. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci 67:2011-2016.
47. Jagannath C, Wells A, Mshvildadze M, Olsen M, Sepulveda E, Emanuele M, Hunter RU, Dasgupta A. 1999. Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci 64:1733-1738.
48. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
49. Bittner B, Guenzi A, Fullhardt P, Zuercher G, Gonzalez RC, Mountfield RJ. 2002. Improvement of the bioavailability of colchicine in rats by coadministration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung 52:684-688.
50. Rege BD, Kao JP, Polli JE. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237-246.
51. Föger F, Schmitz T, Bernkop-Schnürch A. 2006. In vivo evaluation of an oral delivery system for P-gp Substrates based on thiolated chitosan. Biomaterials 27:4250-4255.
52. Föger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnürch A. 2006. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27:5855-5860.
53. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155.
54. Lacombe O, Woodley J, Solleux C, Delbos JM, Boursier-Neyret C, Houin G. 2004. Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci 23:385-391.
55. Baluom M, Friedman M, Rubinstein A. 2001. Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J Control Release 70:139-147.
56. Wigler PW, Patterson FK. 1994. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta 1189:1-6.
57. Kodawara T, Masuda S, Wakasugi H, Uwai Y, Futami T, Saito H, Abe T, Inu K. 2002. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 19:738-743.
58. Baluom M, Friedman DI, Rubinstein A. 1997. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int J Pharm 154:235-243.
59. Perloff MD, Stormer E, von Moltke LL, Greenblatt DJ. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20:1177-1183.
60. Höllt V, Kouba M, Dietel M, Vogt G. 1992. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43:2601-2608.
61. Barancik M, Polekova L, Mrazova T, Breier A, Stankovicova T, Slezak J. 1994. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp Clin Res 20:13-18.
62. Wandel C, Kim RB, Guengerich FP, Wood AJ. 2000. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 28:895-898.
63. Aebi S, Schnider TW, Los G, Heath DD, Darrah D, Kirmani S, McClay EF, D'Agostino H, Plaxe SC, Fink D, De las Alas MM, Howell SB, Christen RD. 1999. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 44:259-265.
64. Gruol DJ, Bourgeois S. 1994. Expression of the mdrl P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis. Biochem Cell Biol 72:561-571.
65. Kirk J, Syed SK, Harris AL, Jarman M, Roufogalis BD, Stratford IJ, Carmichael J. 1994. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48:277-285.
66. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ. 2001. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130-3141.
67. Walker J, Martin C, Callaghan R. 2004. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594-605.